11results about How to "No obvious toxicity" patented technology

The invention discloses paenibacillus kribbensis exopolysaccharide and application thereof in prevention and control of iridovirus diseases of micropterus salmoides. The invention provides a paenibacillus kribbensis exopolysaccharide. The paenibacillus kribbensis exopolysaccharide is prepared from a fermentation product of a paenibacillus kribbensis space mutation delta PS04-17 strain. As a fish feed additive, the paenibacillus kribbensis exopolysaccharide has better in-vivo safety, has a promoting effect on the growth of the largemouth bass, and can promote the growth and weight gain of the largemouth bass and reduce the feed coefficient of the largemouth bass. Meanwhile, as a drug for resisting LMBV virus infection, the compound can inhibit expression of viruses in target tissues, alleviate virus-induced fish body target tissue structure damage and reduce the death rate caused by virus infection. Besides, the paenibacillus kribbensis exopolysaccharide serving as a disease-resistant immunopotentiator can maintain intestinal health of the micropterus salmoides, is simple to prepare, low in cost and easy to obtain in quantity, and provides more products and methods for prevention and control of the iridovirus disease of the micropterus salmoides.

The invention discloses a cryopreserved dental sac mesenchymal stem cell injection as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The cryopreserved dental sac mesenchymal stem cell injection comprises a cryopreservation protection solution and human dental sac mesenchymal stem cells MSC with the preservation number of CCTCC NO: C2024384, wherein the cryopreservation protection solution comprises 8 to 12 parts of human serum albumin, 35 to 45 parts of a sodium chloride injection and 45 to 55 parts of a CryoStorCS10 cell cryopreservation solution; the density of the dental sac mesenchymal stem cells is 0.5 * 10 < 7 >-20 * 10 < 7 > cells / mL. The invention further discloses a preparation method of the injection and application of the injection in preparation of drugs for preventing or / and treating periodontal diseases. The injection can be directly used after being unfrozen, can maintain the activity and the biological performance of the dental sac mesenchymal stem cells, enhances the osteogenesis and cartilage formation capabilities of the dental sac mesenchymal stem cells, and has a good effect of treating periodontal diseases.

The invention belongs to the field of biological medicine, and discloses a preparation method and application of a mesenchymal stem cell-derived exosome entrapped valproic acid compound. According to the invention, the mesenchymal stem cell source exosome is used as a carrier, valproic acid is entrapped, and the compound of VPA entrapped by the exosome of MSCs is prepared by an ultrasonic method, so that the VPA-EXO prepared by the invention is proved to be capable of promoting faster repair of the wound surface by inhibiting inflammation, promoting collagen formation, accelerating angiogenesis and reepithelization of the wound surface. The valproic acid-loaded human umbilical cord mesenchymal stem cell exosome prepared by the invention is VPA-EXO prepared by an ultrasonic method, has no obvious toxicity to cells, and has obvious advantages.

The application discloses a small cell lung cancer treatment target and application thereof. The application proves, through experimental research, that UBE2S has a specific high expression feature in small cell lung cancer (SCLC). The application of UBE2S as a target in development or design of a drug for treating SCLC is disclosed, and the application of a UBE2S targeted inhibitor in preparation of a drug for treating SCLC is disclosed. Odetiglucan can be used as a polysaccharide small molecule compound and can selectively inhibit SCLC cells with high expression of UBE2S. The application provides a new target and a drug research and development direction for precise treatment of SCLC.

This invention discloses a periodontitis-targeted antibacterial supramolecular material, its preparation method, and its application. It belongs to the field of catalyst technology. The preparation method of the periodontitis-targeted antibacterial supramolecular material includes the following steps: dissolving 2,5-dihydroxyterephthalic acid and tetrakis(4-aminophenyl)porphyrin in a first solvent, adding a first catalyst to react, and obtaining a DHA-TAPP COF skeleton; dispersing the DHA-TAPP COF skeleton in a second solvent, adding 3-bromopropyltrimethylammonium bromide and a second catalyst to react, and obtaining Q-COF; dispersing Q-COF in a third solvent, mixing it with H2PtCl6 solution, and then placing it under light conditions to obtain Pt-Q-COF; dispersing Pt-Q-COF in a buffer solution, adding pyruvate oxidase for adsorption treatment, and obtaining POx-Pt-Q-COF. This invention achieves a synergistic effect of "targeted enrichment - dual ROS generation - closed-loop H2O2 supply" through material structure design and functional unit integration, thereby improving the clearance efficiency of periodontal pathogens while ensuring biocompatibility.

The invention discloses a 2-amido substituted aza-heteroaryl compound as well as a pharmaceutical composition and application thereof, the structure of the compound is as shown in formula (I), and the compound also comprises a stereoisomer, a tautomer, a deuterated compound, a pharmaceutically acceptable salt or a mixture of the stereoisomer, the tautomer, the deuterated compound and the pharmaceutically acceptable salt. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compounds disclosed herein. # imgabs0 #

The present application relates to the technical field of biological medicine, and particularly relates to a luteolin and chrysin complex and application thereof in improving insulin resistance drugs, wherein the molar ratio of luteolin to chrysin in the complex is 1:1. The present application discloses, for the first time, the synergistic hypoglycemic mechanism of the complex with the specific ratio through in vitro enzymatic experiments, insulin resistance cell models, and verification of transcriptomics, metabolomics and molecular biology. The complex can not only synergistically inhibit alpha-amylase and alpha-glucosidase activities to reduce postprandial blood glucose, but also improve insulin resistance in multiple dimensions and multiple targets by synergistically regulating the PI3K-AKT signaling pathway, inhibiting IL-17 / NF-kappa B-mediated inflammatory response and regulating fat decomposition and anabolism. The complex provided by the present application has the advantages of significant synergistic effect, clear mechanism of action, high safety and the like, and provides a new choice for developing a novel natural source hypoglycemic drug.

The invention relates to an HTLV-1 virus inhibition drug and application thereof, and belongs to the technical field of virus biology. Specifically, the tegillarca granosa active peptide is extracted from the tegillarca granosa through acid pretreatment and pepsase, so that the tegillarca granosa active peptide is obtained. Experimental results show that the tegillarca granosa active peptide can significantly inhibit proliferation of HTLV-1 positive cell strains (such as ATL-2) within the concentration range of 50-400 [mu] g / mL, and meanwhile expression of Tax and Gag genes in HTLV-1 viruses is effectively reduced. In addition, the prepared tegillarca granosa active peptide has no obvious toxicity to a normal human cell strain (HEK293), which indicates that the tegillarca granosa active peptide has good safety and selectivity. Therefore, the active peptide can be used as a potential medicine for treating HTLV-1 virus related diseases (such as adult T cell leukemia / lymphoma).

The invention discloses an application of Harman alkali in the aspect of preparing a Pseudomonas plecoglossicida inhibitor, and is characterized in that the Harman alkali is applied in the aspect of preparing a medicine for preventing and / or treating aquatic animal infectious diseases caused by Pseudomonas plecoglossicida. The invention further provides application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating aquatic animal plecoglossus altivelis pseudomonas infection, application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating plecoglossus altivelis liver injury, application of a plecoglossus altivelis immunoregulation medicine and application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of an aquaculture feed additive. The method has the advantages that the survival rate of aquatic animals can be remarkably increased in a Pseudomonas plecoglossicida infection model, the bacterial load in immune tissues such as blood, liver, spleen, head and kidney and the like is reduced, and liver and spleen tissue pathological injury and cell apoptosis caused by infection are relieved; meanwhile, harmine can improve biochemical and antioxidant indexes of infection-related serum, and has no obvious toxicity to fish-derived cells within a certain concentration range.

The application discloses injectable long-acting collagen and a preparation method and application thereof, and belongs to the technical field of collagen preparation. The application solves the problems of rapid degradation and insufficient mechanical property of collagen after injection into the body, and the problem of inability to have biological safety, good biological activity and injectability. The long-acting collagen is prepared by taking methoxypolyethylene glycol active ester and collagen as raw materials. Amide reaction is caused between the methoxypolyethylene glycol active ester and lysine residues on the collagen, hydrophilic PEG is introduced on the surface of the collagen, a hydration layer is formed, biological enzymes are hindered from contacting the collagen, collagen degradation is delayed, and the single-arm structure of the methoxypolyethylene glycol active ester can avoid product agglomeration and abnormal viscosity caused by excessive cross-linking. The long-acting collagen has a long retention time in the body, has no obvious cytotoxicity, has high biological safety, and maintains cell proliferation, migration and adhesion activity and biological repair functions.

This invention relates to a selenium-modified gold nanocomplex encapsulated in ginger exosomes, its preparation method, and its applications, belonging to the fields of biomedical technology and nanomedicine formulations. The complex is assembled from L-selenomethylselenocysteine-modified gold nanoparticles as the core and ginger exosomes as the shell. The preparation method includes: first, preparing selenium-modified gold nanoparticles via a one-step reduction method, then mixing and incubating them with ginger exosomes in a specific ratio to obtain the GE-Se-Au complex. This invention's complex directly inhibits tumor cell proliferation by downregulating the p-ERK / c-Myc pathway, while simultaneously inducing macrophage M1 polarization to remodel the immune microenvironment, achieving a synergistic effect between chemotherapy and immunotherapy. In vitro and in vivo experiments show that this complex has a significant inhibitory effect on drug-resistant non-small cell lung cancer, with extremely low toxicity to normal cells and major organs, demonstrating good biocompatibility. This invention features a simple preparation process and strong targeting, providing a new strategy for overcoming drug resistance in lung cancer clinically.